

Haematologica
HAEMATOL/2018/205476
Version 4

Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial

Ruth Wester, Bronno van der Holt, Emelie Asselbergs, Sonja Zweegman, Marie Jose Kersten, Edo Vellenga, Marinus van Marwijk Kooy, Okke de Weerd, Monique Minnema, Sarah Lonergan, Antonio Palumbo, Henk Lokhorst, Annemiek Broijl, and Pieter Sonneveld

Disclosures: Ruth Wester: none. Bronno van der Holt: none. Emelie Asselbergs: none. Sonja Zweegman: advisory boards en research funding Janssen, Celgene, Takeda. Marie Jose Kersten: Honoraria: Novartis, Kite Pharma, Roche, Celgene, Takeda, Mundipharma, Gilead, BMS, MSD, Amgen. Research funding: Roche, Celgene, Takeda Edo Vellenga: none Marinus van Marwijk Kooy: none. Okke de Weerd: none. Monique Minnema: Advisory board Celgene, Takeda, Janssen, Amgen, BMS, Servier. Research support Celgene. Sarah Lonergan: none. Antonio Palumbo: Employment: Takeda. Honoraria + Consultancy: Amgen, Novartis, Bristol-Myers Squibb, Genmab A/S, Celgene, Janssen-Cilag, Takeda, Sanofi Aventis, Merck, Research funding: Amgen, Novartis, Bristol-Myers Squibb, Genmab A/S, Celgene, Janssen-Cilag, Takeda, Sanofi Aventis, Merck, Binding Site Henk Lokhorst: none. Annemiek Broijl: Honoraria Celgene, Janssen, Amgen, BMS Pieter Sonneveld: Research support to institution: Amgen, Celgene, Janssen, Karyopharm, SkylineDx, Takeda Advisory Boards: Amgen, Celgene, Janssen, Karyopharm, SkylineDx, Takeda Honoraria: Amgen, Celgene, Janssen, Karyopharm, Takeda

Contributions: RW and AB wrote the manuscript BH performed data analysis EA and SL performed research PS supervised the study SW, MK, EV, MMK, OW, MM, AP and HL delivered data and critically reviewed the manuscript